Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution

Data from a single-center prospective cohort study of the anti-SARS-CoV-2 BNT162b2 mRNA vaccine among patients receiving treatment for either multiple myeloma (MM) or myeloproliferative malignancies (MPM), which included chronic myeloid leukemia and MPNs, as well as elderly controls who did not have cancer, demonstrated a better response in the control and MPM arms versus the MM arm. At 5 weeks post-vaccination, geometric mean concentration of IgG was 353.3, 172.9 (p = 0.049), and 106.7 AU/mL (p = 0.003), respectively.